|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 2/09/16 Sanofi 6-K 2/09/16 5:918K RR Donnelley/FA |
Document/Exhibit Description Pages Size 1: 6-K Report by a Foreign Private Issuer HTML 13K 2: EX-99.1 Miscellaneous Exhibit HTML 604K 3: EX-99.2 Miscellaneous Exhibit HTML 11K 4: EX-99.3 Miscellaneous Exhibit HTML 15K 5: EX-99.4 Miscellaneous Exhibit HTML 31K
| 6-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2016
Commission File Number: 001-31368
SANOFI
(Translation of registrant’s name into English)
54, rue La Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
In February 2016, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.4 which are incorporated herein by reference.
Exhibit List
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press release dated February 9, 2016: Annual Financial Results for 2015 | |
| Exhibit 99.2 | Press release dated February 5, 2016: Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development | |
| Exhibit 99.3 | Press release dated February 2, 2015: Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine | |
| Exhibit 99.4 | Genzyme Product Sales Statement, for the Product Sales Measuring Period ended December 31, 2015. | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: February 9, 2016 | SANOFI | |||||
| By | /S/ Alexandra Roger | |||||
| Name: | Alexandra Roger | |||||
| Title: | Head of Securities Law and Capital Markets | |||||
3
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press release dated February 9, 2016: Annual Financial Results for 2015 | |
| Exhibit 99.2 | Press release dated February 5, 2016: Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development | |
| Exhibit 99.3 | Press release dated February 2, 2015: Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine | |
| Exhibit 99.4 | Genzyme Product Sales Statement, for the Product Sales Measuring Period ended December 31, 2015. | |
4
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period End: | 2/9/16 | |||
| 2/5/16 | ||||
| 12/31/15 | ||||
| 2/2/15 | 4, 4/A, SC 13G/A | |||
| List all Filings | ||||